Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms
Open accessThe DOI matches its Crossref record.
Abstract
Daptomycin exhibits in vitro bactericidal activity against clinically significant gram-positive bacteria. We employed pharmacodynamic modeling to determine a once-daily dosing regimen of daptomycin that correlates to pharmacodynamic endpoints for different resistant gram-positive clinical strains. An in vitro pharmacodynamic model with an initial inoculum of 6 log 10 CFU/ml was used to simulate daptomycin regimens ranging in dose from 0 to 9 mg/kg of body weight/day, with corresponding exposures reflecting free-daptomycin concentrations in serum. Bacterial density was profiled over 48 h for two methicillin-resistant Staphylococcus aureus (MRSA-67 and -R515), two glycopeptide intermediate-resistant S. aureus (GISA-992 and -147398), and two vancomycin-resistant Enterococcus faecium (VREF-12366 and -SF12047) strains. A sigmoid dose-response model was used to estimate the effective dose required to achieve 50% (ED 50 ) and 80% (ED 80 ) bacterial density reduction at 48 h. Daptomycin MICs for study isolates ranged from 0.125 to 4 μg/ml. Model fitting resulted in an r 2 of >0.80 for all tested isolates. Control growths at 48 h ranged from 7.3 to 8.5 log 10 CFU/ml. Sigmoid relationships were not superimposable between categorical resistant species: ED 50 and ED 80 values were 1.9 and 3.1, 4.2 and 5.6, and 5.4 and 6.8 mg/kg for MRSA, GISA, and VREF isolates, respectively. Doses required to achieve ED 50 and ED 80 values correlated with MIC differences between tested organisms. Corresponding area under the concentration-time curve from 0 to 24 h/MIC exposure ratios demonstrated a wide range of ED 80 values among the tested isolates. Doses ranging between 3 and 7 mg/kg produced significant bactericidal activity (ED 80 ) against these multidrug-resistant S. aureus and E. faecium isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh546 · Cited by 561
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
French, G. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl393 · Cited by 441
Cui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Carpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358
Munita, J. M., Panesso, D., Diaz, L., Tran, T. T., Reyes, J., Wanger, A., Murray, B. E., & Arias, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00509-12 · Cited by 118
Metadata
- Authors
- Cha, R., Grucz, R. G., & Rybak, M. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-05
- Volume
- 47
- Issue
- 5
- Pages
- 1598-1603
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2132927558
- Cited by
- 94
- References
- 0
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms. https://app.cochat.ai/papers/10.1128/aac.47.5.1598-1603.2003
- The paper
- Cha, R., Grucz, R. G., & Rybak, M. J. (2003). Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.47.5.1598-1603.2003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.